First-line pharmacological treatment for acute migraine

First-line pharmacological treatment for acute migraine in adults prioritizes triptans , either as monotherapy or in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) ^[6]B2a[9]B2a. Eletriptan is the most effective oral monotherapy for achieving pain freedom at 2 hours (OR 5.19, 95% CI 4.25-6.33) ^[9]B2a. For pediatric and adolescent populations, ibuprofen and acetaminophen are supported for pain relief, while sumatriptan / naproxen and zolmitriptan nasal spray are recommended for 2-hour pain freedom in adolescents ^[1]A1c.

Comparative Efficacy

Network meta-analyses indicate that triptans are superior to acetaminophen (low certainty) and NSAIDs (high certainty) for 2-hour pain outcomes ^[6]B2a. Combinations of a triptan plus an NSAID provide greater efficacy than triptan monotherapy (moderate certainty) or gepants (low certainty) ^[6]B2a. For sustained pain freedom up to 24 hours, eletriptan and ibuprofen demonstrate the highest efficacy ^[9]B2a.

Alternatives for Triptan-Insufficient Responders

In patients with contraindications or insufficient response to triptans , gepants and ditans are effective alternatives ^{[3]A1a[7]B2a[12]A1b}. Rimegepant 75 mg ODT achieved 2-hour pain relief in 55.9% of triptan-unsuitable patients compared to 32.7% for placebo (p < 0.0001; NNT = 5) ^[12]A1b. Lasmiditan 200 mg shows high cumulative probability for 2-hour pain freedom in triptan-insufficient responders ^[7]B2a.

Pearl: Eletriptan and triptan-NSAID combinations provide the highest probability of 2-hour pain freedom, while rimegepant 75 mg serves as a primary alternative for patients with triptan contraindications ^{[6]B2a[9]B2a[12]A1b}. (High, multiple meta-analyses and RCTs)

Traditional management of acute migraine relied heavily on simple analgesics, ergotamine derivatives, and amitriptyline , though these often resulted in inadequate pain relief or significant side effects ^[8]B2a. The therapeutic landscape shifted with the introduction of triptans, which established a new standard for efficacy. A network meta-analysis of 137 randomized trials involving 89,445 participants confirmed that all licensed oral monotherapies, particularly triptans, are superior to placebo for pain freedom at 2 hours ^[9]B2a. Among these, eletriptan emerged as the most effective agent for 2-hour pain freedom (OR 5.19, 95% CI 4.25-6.33) and sustained relief up to 24 hours ^[9]B2a.

Shift Toward Combination and Targeted Therapy

Clinical practice evolved from simple monotherapy to combination regimens to address incomplete responses. Triptan and NSAID combinations proved more effective for 2-hour pain outcomes than triptan monotherapy (moderate COE) or acetaminophen (low COE) ^[6]B2a. While triptans remain more effective than acetaminophen (low COE) and NSAIDs (high COE) alone, they are associated with a higher risk of adverse events ^[6]B2a. For specific populations, such as those with menstrual migraine, sumatriptan and lasmiditan became preferred first-line options due to high odds of 2-hour pain relief (OR 4.62) ^[10]B2a.

Emergence of Non-Vasoconstrictive Alternatives

The most recent evolution involves the development of ditans and gepants for patients with cardiovascular contraindications or insufficient responses to triptans ^[3]A1a[7]B2a. Unlike triptans, these agents do not cause vasoconstriction. Rimegepant 75 mg demonstrated a significant 2-hour pain freedom advantage over placebo (RR 1.77, 95%; NNT = 13 based on typical event rates) with a safety profile comparable to placebo ^[3]A1a. In triptan-insufficient responders, lasmiditan , rimegepant , and ubrogepant all showed significant superiority over placebo, with high-dose lasmiditan 200 mg achieving the highest cumulative probability for pain control ^[7]B2a.

Pearl: Eletriptan is the most effective oral monotherapy for rapid and sustained pain freedom ^[9]B2a, though the emergence of gepants like rimegepant provides a critical non-vasoconstrictive alternative for triptan-insufficient responders ^[3]A1a[7]B2a.

Triptans remain the most effective oral monotherapy for achieving 2-hour pain freedom compared to acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) ^[6]B2a. In a network meta-analysis of 137 randomized trials, eletriptan demonstrated the highest efficacy for 2-hour pain freedom (OR 5.19, 95% CI 4.25-6.33) compared to placebo, followed by rizatriptan , sumatriptan , and zolmitriptan ^[9]B2a. For sustained pain freedom up to 24 hours, eletriptan and ibuprofen were the most efficacious interventions ^[9]B2a.

Combination and Comparative Efficacy

Combination therapy involving a triptan and an NSAID is more effective for 2-hour pain outcomes and 48-hour pain freedom than triptan monotherapy (moderate COE), gepants (low COE), or acetaminophen (low COE) ^[6]B2a. While triptans and their combinations offer superior efficacy, they are associated with a higher risk of adverse events compared to simpler analgesics ^[6]B2a. In the pediatric emergency setting, ketorolac is effective for acute migraine but has not demonstrated superiority over opioids or other NSAIDs ^[5]B2a.

Novel Therapies for Triptan-Insufficient Responders

For patients who are unsuitable for triptans due to contraindications, intolerance, or lack of efficacy, calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) and ditans provide effective alternatives ^{[3]A1a[7]B2a[12]A1b}.

• Lasmiditan and Ubrogepant : In triptan-insufficient responders, lasmiditan , rimegepant , and ubrogepant were all superior to placebo for 2-hour pain freedom (RR 1.93, 95% CI 1.52-2.46) ^[7]B2a. Lasmiditan 200 mg showed the highest cumulative probability for pain control in this subgroup ^[7]B2a.

Special Populations and Adjunctive Care

In menstrual migraine (MM), sumatriptan and lasmiditan are effective first-line options for acute relief (OR 4.62 for 2-hour relief) ^[10]B2a. For patients with medication overuse (MO), the initiation of preventive anti-CGRP monoclonal antibodies such as eptinezumab , fremanezumab , galcanezumab , or erenumab significantly aids the transition to non-overuse status (RR 1.44, 95% CI 1.31-1.59) ^[11]B2a.

In the emergency department, adding 1,000 mL intravenous saline to 75 mg intramuscular diclofenac did not significantly improve 2-hour VAS pain scores (between-group difference 10.0 mm, 95% CI -2.0 to 20.0) ^[13]A1b. However, it was associated with lower rescue medication use (23.8% vs 42.5%; absolute difference 18.6%, 95% CI 2.1-35.0) ^[13]A1b. Non-pharmacological mindfulness-based interventions significantly reduce pain intensity (SMD 0.23) and frequency (SMD 0.33) but do not significantly reduce the acute use of triptans or analgesics ^[4]B2a.

Controversies and Guideline Disagreement

Pearl: Eletriptan is the most effective oral monotherapy for rapid pain freedom, while a single 75 mg dose of rimegepant is the evidence-based standard for patients who cannot tolerate or fail triptans ^{[9]B2a[12]A1b}.

Clinical evidence for acute migraine interventions varies significantly across specific patient populations, particularly those with contraindications to traditional therapies or those experiencing medication overuse. While triptans remain the standard for many, their vasoconstrictive mechanism limits use in patients with cardiovascular disease ^[3]A1a.

Triptan-Unsuitable and Insufficient Responders

For adults unsuitable for triptans due to intolerance, lack of efficacy, or contraindications, rimegepant 75 mg provides a validated alternative ^[12]A1b. In a phase 4 trial of this population, rimegepant achieved 2-hour pain relief in 55.9% of patients compared to 32.7% for placebo (p < 0.0001) ^[12]A1b. Among patients who self-report insufficient response to triptans , lasmiditan , rimegepant , and ubrogepant all demonstrate significant superiority over placebo for 2-hour pain freedom (RR 1.93, 95% CI 1.52-2.46) ^[7]B2a. High-dose lasmiditan 200 mg may offer the highest probability for pain control in this subgroup ^[7]B2a.

Menstrual and Pediatric Populations

Menstrual migraine (MM) often presents with greater severity and longer duration than typical attacks ^[10]B2a. Sumatriptan and lasmiditan are effective first-line options for acute MM, with sumatriptan and lasmiditan demonstrating superior pain relief at 2 hours (OR 4.62) ^[10]B2a. In pediatric emergency settings, evidence for ketorolac remains limited ^[5]B2a. While effective for acute pain, ketorolac has not shown significant differences in analgesic performance compared to opioids or other NSAIDs in children ^[5]B2a.

Medication Overuse and Comorbidities

Patients with episodic or chronic migraine and concurrent medication overuse (MO) may benefit from anti-CGRP monoclonal antibodies to transition to non-overuse status (RR 1.44, 95% CI 1.31-1.59) ^[11]B2a. This effect is most pronounced in those overusing triptans (RR 1.71) but was not statistically significant for those overusing simple analgesics ^[11]B2a. Additionally, integrating mindfulness-based interventions can reduce pain intensity (SMD 0.23) and frequency (0.33) without increasing the burden of pharmacological side effects ^[4]B2a.

Pearl: For patients with cardiovascular contraindications or triptan failure, CGRP antagonists like rimegepant 75 mg provide a safe and effective alternative, achieving 2-hour pain relief in over 50% of triptan-unsuitable adults ^{[3]A1a[12]A1b}.

Emerging evidence suggests that ubrogepant and atogepant demonstrate consistent efficacy across biological sexes, addressing a historical data gap in male populations ^[18]B2a. Pooled phase 3 data for ubrogepant showed 2-hour pain freedom rates of 19.4% in males versus 21.1% in females, with similar sustained relief through 48 hours ^[18]B2a. For patients who self-report an insufficient response to triptans , network meta-analyses of phase 3 trials indicate that lasmiditan , rimegepant , and ubrogepant are all significantly superior to placebo for 2-hour pain freedom (RR 1.93, 95% CI 1.52-2.46) ^[7]B2a. High-dose lasmiditan 200 mg currently holds the highest cumulative probability for achieving 2-hour pain freedom in this refractory subgroup (SUCRA 0.9) ^[7]B2a.

Biomarkers and Discontinuation Dynamics

Efforts to identify predictive biomarkers for CGRP -targeted therapies have encountered early setbacks. The CGRP-provocation model, which uses CGRP infusion to induce attacks, failed to predict response to erenumab ; 61% of CGRP-sensitive patients achieved a ≥50% reduction in monthly migraine days compared to 52% of non-sensitive patients (p = 0.498) ^[20]A1b.

Regarding treatment cessation, meta-analysis data show that while migraine burden worsens after discontinuing anti-CGRP monoclonal antibodies, it remains lower than pre-treatment levels ^[17]B2a. Monthly migraine days increased by 4.43 days (95% CI 2.61-6.25) at 3 months post-discontinuation compared to the active treatment period, yet remained 3.78 days below the original baseline ^[17]B2a.

Pearl: Novel agents like lasmiditan and gepants provide effective rescue for triptan-insufficient responders, though high-dose lasmiditan may offer superior 2-hour pain control ^[7]B2a.